StreetInsider.com News Articles

Vera Therapeutics to Participate at Upcoming Investor Conferences

Tue, 01 Sep 2026 07:30:00 -0400

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.

Investor Conference Details:

Cantor Global Healthcare Conference 2026
Format: Fireside Chat and 1x1 investor meetings
Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=39555950&checkCompany=1&checkEmail=1&checkName=1
Date: Thursday, September 10, 2026
Time: 8:00am ET
Location: New York, NY

Morgan Stanley 24^th Annual Global Healthcare Conference
Format: Fireside Chat and 1x1 investor meetings
Webcast: https://cc.webcasts.com/morg007/091426a_js/?entity=62_7WR7U8U
Date: Tuesday, September

Vera Therapeutics to Participate at Upcoming Investor Conferences

Tue, 01 Sep 2026 07:30:00 -0400

Investor Conference Details:

Cantor Global Healthcare Conference 2026
Format: Fireside Chat and 1x1 investor meetings
Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=39555950&checkCompany=1&checkEmail=1&checkName=1
Date: Thursday, September 10, 2026
Time: 8:00am ET
Location: New York, NY

Morgan Stanley 24^th Annual Global Healthcare Conference
Format: Fireside Chat and 1x1 investor meetings
Webcast: https://cc.webcasts.com/morg007/091426a_js/?entity=62_7WR7U8U
Date: Tuesday, September

Increasing unusual call volume: DKS CCCC IMPP VERA EMBJ GMAB DUST BCS KHC SOLZ SN ANF AI PLAB

Wed, 26 Aug 2026 10:40:39 -0400

Increasing unusual call volume: DKS CCCC IMPP VERA EMBJ GMAB DUST BCS KHC SOLZ SN ANF AI PLAB

Increasing unusual option volume: DKS VERA CRON BBWI AS ARDX VSTM ENR MAIN EWZ XE

Wed, 26 Aug 2026 03:11:39 -0400

Increasing unusual option volume: DKS VERA CRON BBWI AS ARDX VSTM ENR MAIN EWZ XE

Vera Therapeutics Inc. (VERA) spreader of 6430 contracts of September 35 and 45 calls, share price up 3.1%

Tue, 25 Aug 2026 15:23:38 -0400

Vera Therapeutics Inc. (NASDAQ: VERA) 30-day option implied volatility is at 78; compared to its 52-week of 63 to 150 with a focus on a spreader of 6430 contracts of September 35 and 45 calls as share price up 3.1%.

Form SCHEDULE 13G/A Vera Therapeutics, Inc. Filed by: Kynam Capital Management, LP

Fri, 14 Aug 2026 12:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26927716.html

Form SCHEDULE 13G/A Vera Therapeutics, Inc. Filed by: Kynam Capital Management, LP

Fri, 14 Aug 2026 12:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26927716.html

Form 4/A Vera Therapeutics, Inc. For: Jul 07 Filed by: Fordyce Marshall

Wed, 12 Aug 2026 18:43:00 -0400

si-local-file:///var/storage/secattach/20260812/26914684.html

Form 4/A Vera Therapeutics, Inc. For: Jul 07 Filed by: Fordyce Marshall

Wed, 12 Aug 2026 18:43:00 -0400

si-local-file:///var/storage/secattach/20260812/26914684.html

Form 4/A Vera Therapeutics, Inc. For: Jun 23 Filed by: Fordyce Marshall

Wed, 12 Aug 2026 18:42:00 -0400

si-local-file:///var/storage/secattach/20260812/26914682.html

Form 4/A Vera Therapeutics, Inc. For: Jun 23 Filed by: Fordyce Marshall

Wed, 12 Aug 2026 18:42:00 -0400

si-local-file:///var/storage/secattach/20260812/26914682.html

Form 4/A Vera Therapeutics, Inc. For: May 12 Filed by: Fordyce Marshall

Wed, 12 Aug 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260812/26914679.html

Form 4/A Vera Therapeutics, Inc. For: May 12 Filed by: Fordyce Marshall

Wed, 12 Aug 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260812/26914679.html

Vera Therapeutics (VERA) PT Lowered to $80 at Goldman Sachs

Wed, 12 Aug 2026 16:29:47 -0400

Goldman Sachs analyst Paul Choi lowered the price target on Vera Therapeutics (NASDAQ: VERA) to $80.00 (from $90.00) while maintaining a Buy rating.

The analyst comments "Awaiting eGFR data in 3Q, potential updates at Kidney Week, and early Trutakna launch progress. VERA reported 2Q26 results, which we view as largely uneventful as investor focus remains largely on data updates, the competitive landscape, and measures of early progress with the Trutakna (atacicept) launch. Operating expenses of $112mn came in -13% below GSe of $129mn with lower R&D expense offset by higher SG&A costs, which resulted in a smaller loss per share of

Vera Therapeutics (VERA) PT Lowered to $80 at Goldman Sachs

Wed, 12 Aug 2026 16:29:47 -0400

Goldman Sachs analyst Paul Choi lowered the price target on Vera Therapeutics (NASDAQ: VERA) to $80.00 (from $90.00) while maintaining a Buy rating.

Vera Therapeutics (VERA) PT Lowered to $90 at H.C. Wainwright

Wed, 12 Aug 2026 07:25:38 -0400

(Updated - August 12, 2026 7:25 AM EDT)

H.C. Wainwright analyst Arthur He lowered the price target on Vera Therapeutics (NASDAQ: VERA) to $90.00 (from $125.00) while maintaining a Buy rating.

The analyst commented: "At GlomCon Hawaii 2026 on August 3, Otsuka presented complete two-year data from the Phase 3 VISIONARY trial evaluating Voyxact (sibeprenlimab) in adults with primary IgA nephropathy (IgAN) at risk of progression. The study met its key secondary endpoint: annualized eGFR slope of +0.3 mL/min/1.73m²/y (95% CI, -0.4 to 0.9) on sibeprenlimab (n=259) versus -4.2 (95% CI, -4.9 to -3.6) on placebo (n=251), a treatment difference of +4.5

Vera Therapeutics (VERA) PT Lowered to $90 at H.C. Wainwright

Wed, 12 Aug 2026 07:25:38 -0400

(Updated - August 12, 2026 7:25 AM EDT)

H.C. Wainwright analyst Arthur He lowered the price target on Vera Therapeutics (NASDAQ: VERA) to $90.00 (from $125.00) while maintaining a Buy rating.

Vera Therapeutics, Inc. (VERA) Tops Q2 EPS by 13c

Mon, 10 Aug 2026 17:22:57 -0400

Vera Therapeutics, Inc. (NASDAQ: VERA) reported Q2 EPS of ($1.52), $0.13 better than the analyst estimate of ($1.65).

For earnings history and earnings-related data on Vera Therapeutics, Inc. (VERA) click here.

Form 10-Q Vera Therapeutics, Inc. For: Jun 30

Mon, 10 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260810/26897983.html

Form 10-Q Vera Therapeutics, Inc. For: Jun 30

Mon, 10 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260810/26897983.html

Form 8-K Vera Therapeutics, Inc. For: Aug 10

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897774.html

Form 8-K Vera Therapeutics, Inc. For: Aug 10

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897774.html

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 16:05:00 -0400

TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.
Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026.
Anticipated supplemental Biologics License Application (sBLA) submission to the FDA – expected in Q4 2026.

BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today reported its business highlights and financial results for the quarter

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 16:05:00 -0400

TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.
Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026.
Anticipated supplemental Biologics License Application (sBLA) submission to the FDA – expected in Q4 2026.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:05:00 -0400

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D., Ph.D., Vera’s new Chief Regulatory Officer, under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan), and on August 4, 2026, the Compensation Committee granted inducement awards consisting of non-qualified stock